DANCHURCHAID
18.3.2024 18:07:34 CET | Business Wire | Press release
A coalition of international climate organizations will come together for an event in Copenhagen on the 20 March 2024 to deliver recommendations on integrating climate and development for climate finance to world leaders, ahead of a year of intense negotiations, starting at the Copenhagen Climate Ministerial.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240318208761/en/
Photo: Mathilde Utzon
The year 2024 is of paramount importance for our future. We face an urgent need to handle the climate crisis, within the broader range of Sustainable Development Goals. This year’s high-level meetings leading up to COP29 will focus on climate finance, aiming to address the substantial funding gaps.
To kick-start these discussions DanChurchAid, E3G, the International Institute for Environment and Development, CONCITO, NDC Partnerships, and the UN Foundation are coming together to co-host the virtual and in-person event ‘Integrating Climate and Development for Adaptation Finance’ in Copenhagen on the 20 March, to provide inspiration for the Copenhagen Climate Summit.
“Adaptation finance must be at the heart of the negotiations towards COP29. Adaptation to the consequences of climate change is a question of survival. We need to adapt to a new reality, where droughts, rising sea levels, and heatwaves are becoming increasingly commonplace,” said Secretary General of DanChurchAid, Jonas Nøddekær.
“The countries most vulnerable to climate change have been clear about what they need to adapt to it - more money, on fairer terms and channelled to local people who are best placed to use it. Governments meeting in Copenhagen have a chance to put down a marker for stronger climate outcomes later this year and to show they're taking lower-income nations seriously,” said Ebony Holland, IIED’s nature-climate policy lead.
“The decisions that governments make this year will shape if, how, and how much finance is delivered over the next decade and beyond. We need to make sure that finance is adequate to achieve the Sustainable Development Goals and a climate resilient future for all,” said Cristina Rumbaitis del Rio, Senior Advisor, Adaptation and Resilience, UN Foundation.
“We must be striving for our climate and development goals concurrently and linking the two. For developing countries, adaptation and resilience are both a priority and a tremendous challenge. The NDC Partnership supports countries efforts to raise ambition in ways that are implementable, financeable and help foster more equitable and sustainable development, through effective coordinated support of more than 220 members,” said Pablo Vieira, Global Director of the NDC Partnership.
“Globally, all stakeholders must come together behind a coherent framework for climate finance as presented by the Independent High-Level Group on Climate Finance to massively upscale funding for integrated climate and development action. Country owned climate plans (NDCs) that integrate adaptation and long-term development plans must be turned into investment plans by 2030,” said Chairperson of the Board of CONCITO, Connie Hedegaard.
“The climate and development ministerials have shone a light on the reforms needed to how we do adaptation finance to shift towards more systemic resilience investments. Denmark, Samoa and their co-champions of the adaptation finance vision agreed at last year’s ministerial have a chance to drive a scale up and improvement in adaptation finance over the next couple of years as countries prepare their next climate policy updates,” said Alex Scott, Climate Diplomacy and Geopolitics Programme Lead at E3G
Event details and registration: The event will take place on the 20 March 2024, from 14:00-16:30, at:
DanChurchAid, Meldahlsgade 3, 1613 Copenhagen V, Denmark.
For registration for either online or in-person participation, please send an email to copenhagenevent@dca.dk
For media request please contact Mattias Söderberg, at: msd@dca.dk or +45 29700609.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240318208761/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
